PDF herunterladen
Arzneimittelforschung 2012; 62(02): 75-82
DOI: 10.1055/s-0031-1295484
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics, Pharmacodynamics, and Tolerability of a Generic Formulation of Exenatide: A Randomized, Open-Label, Single- and Multiple-Dose Study in Healthy Chinese Volunteers

S. Shi
1   Clinical Research Organization for Pharmaceutical Products, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue, Wuhan, People’s Republic of China
,
Y. Liu
1   Clinical Research Organization for Pharmaceutical Products, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue, Wuhan, People’s Republic of China
,
Z. Li
1   Clinical Research Organization for Pharmaceutical Products, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue, Wuhan, People’s Republic of China
,
J. Wu
1   Clinical Research Organization for Pharmaceutical Products, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue, Wuhan, People’s Republic of China
2   Institute of Clinical Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
,
X. Zhou
3   Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, People’s Republic of China
,
F. Zeng
1   Clinical Research Organization for Pharmaceutical Products, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue, Wuhan, People’s Republic of China
2   Institute of Clinical Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 02. November 2011

accepted 07. November 2011

Publikationsdatum:
16. Februar 2012 (online)

    Lizenzen und Reprints

Abstract

A randomized, open-label, dose-escalating study was designed to assess the pharmacokinetics, pharmacodynamics and tolerability of single and multiple subcutaneous administrations of exenatide in 24 healthy Chinese volunteers. The effects of gender on the pharmacokinetics of exenatide were also evaluated. Subjects were randomized to receive a single and multiple subcutaneous doses of 5 or 10 μg of exenatide. Following the single dose subjects received exenatide twice daily on days 2–4 and once on day 5. Sequential blood samples were collected at regular intervals from 0 to 8 h after single administration. Concomitantly the serum glucose concentrations were measured in each sample. Tolerability was assessed using physical examination, vital signs, laboratory analysis, and by interview of subjects. Pharmacokinetic parameters for exenatide after subcutaneous administration of a single dose of 5–10 μg were as follows: Cmax=77.7 (13.9) and 136.1 (15.2) pg/mL; AUC0–t=184.2 (49.7) and 309.7 (52.3) pg·h/mL; AUC0–∞=225.8 (77.4) and 365.4 (68.8) pg·h/mL; tmax (median [range])=1.00 (0.75–1.50) and 1.00 (0.75–1.50) h; t1/2 (mean [range])=1.4 (0.7–3.2) and 1.8 (1.0–2.5) h, respectively. Because of its short t1/2, Css, min could not be detected in any plasma samples prior to daily dosing on days 3–5. Pharmacokinetic parameters for exenatide after administration of multiple doses of 5 or 10 μg were as follows: Cmax=81.2 (12.2) and 144.5 (13.3) pg/mL; AUC0–t=181.1 (39.4) and 275.6 (45.0) pg·h/mL; AUC0–∞=217.2 (44.8) and 313.3 (48.4) pg·h/mL; tmax=1.10 (0.75–1.25) and 1.00 (1.00–1.25) h; t1/2=1.6 (0.8–2.2) and 1.4 (0.9–2.7) h, respectively. Both doses of exenatide were associated with significant reductions in serum glucose concentrations (P<0.001) when compared to baseline levels. Mean percentage of maximal decline for serum glucose concentrations after single and multiple doses were 15.6% and 19.9% for 5 μg, respectively; as well as 26.3% and 28.7% for 10 μg, respectively. 12 of the 24 subjects reported a total of 75 adverse events. The rate increased with higher doses of exenatide: after 5 μg only one subject experienced at least 1 adverse event but following 10 μg 11 subjects were affected. 2 subjects receiving the higher dose of 10 μg exenatide dropped out because of adverse events (nausea and vomiting). The most common adverse events were of gastrointestinal origin (e. g. decreased appetite, nausea and vomiting) and of mild severity. In conclusion, in healthy Chinese subjects, AUC and Cmax increased in proportion to the dose, whereas t1/2 was independent of dose. The pharmacokinetic parameters after multiple dosing were consistent with those after single doses. No significant gender differences were noted for pharmacokinetic variables. Both exenatide doses were associated with significant reductions in serum glucose levels. Adverse events were mainly of gastrointestinal origin and their incidence was dose-dependent.

Key words

exenatide - pharmacokinetics - pharmacodynamics - tolerability - healthy - subjects
 

  • References

  • 1 Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; Dec; 414 (6865) 782-787
    CrossrefPubMedGoogle Scholar
  • 2 Nathan DM. Finding new treatments for diabetes – how many, how fast… how good?. N Engl J Med 2007; Feb; 356 (05) 437-440
    CrossrefPubMedGoogle Scholar
  • 3 Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; Jan; 287 (03) 360-372
    CrossrefPubMedGoogle Scholar
  • 4 Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65 (03) 385-411
    CrossrefPubMedGoogle Scholar
  • 5 Rotella CM, Pala L, Mannucci E. Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest 2005; Sep; 28 (08) 746-758
    PubMedGoogle Scholar
  • 6 Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; Jan; 297 (1/2) 127-136
    CrossrefPubMedGoogle Scholar
  • 7 Cornu M, Modi H, Kawamori D et al. Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression. J Biol Chem 2010; Apr; 285 (14) 10538-10545
    CrossrefPubMedGoogle Scholar
  • 8 Siddiqui NI. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh Med J 2009; Jan; 18 (01) 113-124
    PubMedGoogle Scholar
  • 9 Clark WL. Exenatide. From the Gila monster to you. Exenatide is the first of a new class of drugs known as “incretin mimetics” that can enhance your blood glucose control. Diabetes Self Manag 2006; Jan-Feb; 23 (01) 36: 39-40
    PubMedGoogle Scholar
  • 10 Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; Oct; 26 (10) 2929-2940
    CrossrefPubMedGoogle Scholar
  • 11 Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother 2006; Jun; 7 (08) 1055-1064
    CrossrefPubMedGoogle Scholar
  • 12 Cvetković RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007; 67 (06) 935-954
    CrossrefPubMedGoogle Scholar
  • 13 Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006; Dec; 60 (12) 1654-1661
    CrossrefPubMedGoogle Scholar
  • 14 Chakraborti CK. Exenatide: a new promising antidiabetic agent. Indian J Pharm Sci 2010; Jan; 72 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 15 Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition 2010; Mar; 26 (03) 243-249
    CrossrefPubMedGoogle Scholar
  • 16 US Food and Drug Administration. Center for Drug Evaluation and Research (CDER) drug and biologic approvals for calendar year 2005. http://www.fda.gov/cder/rdmt/ndaaps05cy.htm (last accessed on 30 September, 2011)
    PubMedGoogle Scholar
  • 17 Gedulin BR, Smith PA, Jodka CM et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm 2008; May; 356 (1/2) 231-238
    CrossrefPubMedGoogle Scholar
  • 18 Kothare PA, Linnebjerg H, Isaka Y et al. Pharmacokinetics, pharmacodynamics, tolerability and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 2008; Dec; 48 (12) 1389-1399
    PubMedGoogle Scholar
  • 19 Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; Jan; 62 (02) 173-181
    PubMedGoogle Scholar
  • 20 Bray GM. Exenatide. Am J Health Syst Pharm 2006; Mar; 63 (05) 411-418
    CrossrefPubMedGoogle Scholar
  • 21 Zhao X, Cui YM, Zhou Y et al. Exenatide pharmacokinetics in healthy Chinese subjects. Int J Clin Pharmacol Ther 2008; Sep; 46 (09) 459-465
    PubMedGoogle Scholar
  • 22 State Food and Drug Administration Good Clinical Practice Guideline [in Chinese] http://www.sda.gov.cn/WS01/CL0053/24473.html (last accessed on 30 September, 2011)
    PubMed
  • 23 European Agency for the Evaluation of Medicinal Products (EMEA). International Conference on Harmonisation- World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E 6 (R1). Geneva, Switzerland: WHO; 2002. http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf (last accessed on 30 September, 2011)
    Google Scholar
  • 24 World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html (last accessed on 30 September, 2011)
    PubMedGoogle Scholar
  • 25 US Food and Drug Administration . Center for Drug Evaluation and Research (CDER). Guidance for industry, Bioanalytical method validation May 2001; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (last accessed on 30 September, 2011)
    PubMedGoogle Scholar
  • 26 State Food and Drug Administration. Guidance for clinical pharmacokinetic studies of chemical drugs [in Chinese]. http://www.sda.gov.cn/gsz05106/07.pdf (last accessed on 30 September, 2011)
    PubMedGoogle Scholar
  • 27 Chen ZY, Zheng QS, Sun RY. Functions of the DAS software for pharmacological calculation. Chin J Clin Pharmacol Ther 2002; Jun; 7 (06) 562-564
    PubMedGoogle Scholar
  • 28 BYETTA prescribing information [article online]; 2009. Available from http://pi.lilly.com/us/byetta-pi.pdf . (last accessed on 30 September, 2011)
    PubMed
  • 29 Barnett A. Exenatide. Expert Opin Pharmacother 2007; Oct; 8 (15) 2593-2608
    CrossrefPubMedGoogle Scholar
  • 30 Kaushal S, Chopra SC, Arora S. Exenatide: An incretin-mimetic agent. Indian J Pharmacol 2006; 38: 76-78
    CrossrefPubMedGoogle Scholar
  • 31 Copley K, McCowen K, Hiles R et al. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006; May; 7 (04) 367-374
    CrossrefPubMedGoogle Scholar
  • 32 Linnebjerg H, Kothare PA, Park S et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; Sep; 64 (03) 317-327
    CrossrefPubMedGoogle Scholar